FibroBiologics, Inc. (FBLG)
| Market Cap | 7.06M -71.4% |
| Revenue (ttm) | n/a |
| Net Income | -18.14M |
| EPS | -4.77 |
| Shares Out | 6.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181,661 |
| Open | 1.170 |
| Previous Close | 1.150 |
| Day's Range | 1.020 - 1.170 |
| 52-Week Range | 0.620 - 12.800 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 12.50 (+1,079.25%) |
| Earnings Date | Jul 31, 2026 |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FBLG stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 1,079.25% from the latest price.
News
FibroBiologics awarded new patent from USPTO
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibr...
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiol...
FibroBiologics announces EPO granted patent for gene cartilage therapy
FibroBiologics (FBLG) announced that the European Patent Office, or EPO, has granted the Company’s patent entitled “Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells.” The gran...
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathways HOUSTON, Aug. 5, 2026 /PRNewswire/ -- Fibr...
FibroBiologics price target lowered to $6 from $8 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on FibroBiologics (FBLG) to $6 from $8 and keeps a Buy rating on the shares. The firm cites the company’s private placement for…
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026 HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics,...
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics Quarterly report: Q2 2026
FibroBiologics has published its Q2 2026 quarterly earnings report on July 31, 2026.
FibroBiologics Earnings release: Q2 2026
FibroBiologics released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics Registration statement: Registration filing
FibroBiologics filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
FibroBiologics files to sell up to 12.53M shares of common stock
07:20 EDT FibroBiologics (FBLG) files to sell up to 12.53M shares of common stock
FibroBiologics appoints Rubins to its Board of Directors
FibroBiologics (FBLG) announced the appointment of Kathleen “Kate” Rubins, Ph.D. to its Board of Directors. As a retired NASA astronaut, microbiologist, and genomics scientist, Dr. Rubins has conducte...
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins Board HOUSTON, July 9, 2026 /PRNewswire/ -- Fibro...
FibroBiologics completes manufacturing of third batch of CYWC628
FibroBiologics (FBLG) announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers, DFUs. The…
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinica...
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the developme...
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NAS...
FibroBiologics announces $9M private placement priced at-the-market
FibroBiologics (FBLG) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,081,633 shares of common stock, series A warrants to purchase up…
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NAS...
FibroBiologics Transcript: AGM 2026
The meeting covered board changes, approved all four shareholder proposals, and addressed concerns about Nasdaq listing compliance and the impact of potential delisting. Voting results will be reported to the SEC within four business days.
FibroBiologics receives notice of allowance for U.S. patent
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice of allowance for the company’s patent application entitled “Therapeutic Use of Fibrobl...
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical...
FibroBiologics doses first patients in CYWC628 clinical trial
FibroBiologics (FBLG) announced that the first patients have been dosed in the company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers. Initial dosing took plac...
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the devel...